Cell-penetrating peptides for siRNA delivery to glioblastomas (2018)
Sequence: Stearyl-AGYLLGKLLOOLAAAALOOLL-NH2
| Experiment Id | EXP000906 |
|---|---|
| Paper | Cell-penetrating peptides for siRNA delivery to glioblastomas |
| Peptide | PF14:TG4 (non-covalent) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 25 nM |
| Mixing Ratio | PF14:siRNA MR 5–40; PF14:TG4 MR 1/10/100 tested |
| Formulation Format | peptide/siRNA non-covalent nanocomplex |
| Formulation Components | TG4 = EEEEEEX + EPRNEEK (EPRNEEK-NH2); X=6-aminohexanoic acid |
| Size Nm | 5391.00 |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | U87 MG-luc2 (human glioblastoma); HeLa-luc used as non-glioma control in supplemental experiments |
| Animal Model | |
| Administration Route | |
| Output Type | luciferase knockdown |
| Output Value | |
| Output Units | |
| Output Notes | Functional luciferase assay performed in U87 MG-luc2 (Fig.4/5); numerical % knockdown for TG4 not explicitly stated in text. |
| Toxicity Notes | No significant toxicity reported in U87 MG-luc2 at 25 nM siRNA (WST-1, 24 h) across tested MRs for all peptide:siRNA complexes. |
| Curation Notes |